Tranquility Partners LLC Sells 476 Shares of Zoetis Inc. (NYSE:ZTS)

Tranquility Partners LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.9% in the fourth quarter, HoldingsChannel reports. The fund owned 7,645 shares of the company’s stock after selling 476 shares during the period. Tranquility Partners LLC’s holdings in Zoetis were worth $1,246,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZTS. AMF Tjanstepension AB raised its position in shares of Zoetis by 23.4% during the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after acquiring an additional 20,001 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in Zoetis by 4,582.9% in the third quarter. Exchange Traded Concepts LLC now owns 1,639 shares of the company’s stock valued at $320,000 after purchasing an additional 1,604 shares during the last quarter. CX Institutional increased its holdings in Zoetis by 6.3% in the third quarter. CX Institutional now owns 8,142 shares of the company’s stock valued at $1,591,000 after purchasing an additional 482 shares during the last quarter. Creative Planning increased its holdings in Zoetis by 8.6% in the third quarter. Creative Planning now owns 90,401 shares of the company’s stock valued at $17,663,000 after purchasing an additional 7,170 shares during the last quarter. Finally, 626 Financial LLC bought a new stake in Zoetis in the third quarter valued at about $212,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.2 %

ZTS stock opened at $173.99 on Thursday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The stock has a market capitalization of $78.50 billion, a P/E ratio of 32.70, a P/E/G ratio of 2.77 and a beta of 0.90. The business has a 50-day moving average of $169.11 and a 200-day moving average of $179.11. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.15%. Zoetis’s dividend payout ratio is currently 37.59%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of recent analyst reports. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Morgan Stanley dropped their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Stifel Nicolaus dropped their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $214.00.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.